Evoke Wealth’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Evoke Wealth’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	–	–	1258
2021 Q3	$0	Buy	+100	New	+$763	﹤0.01%	1235

Other funds holding DBTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Evoke Wealth's DBTX Position: Q4 2021 in Review

Evoke Wealth sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q4 2021, closing a stake of 100 shares.

Evoke Wealth first reported a position in DBTX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 40 funds tracked by Wall St. Rank hold DBTX as of Q4 2021.

Evoke Wealth reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Evoke Wealth sold 100 Decibel Therapeutics, Inc. Common Stock shares in Q4 2021.
Evoke Wealth first reported a position in Decibel Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
Evoke Wealth's Decibel Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2021.
40 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Evoke Wealth's 13F filing for Q4 2021, filed 9 Feb 2022.